Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial-Reference-Cited by-同舟云学术

Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial

Published:2024-06 Issue:6 Volume:85 Page:517-520
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Nikitas John,Rettig Matthew,Shen John,Reiter Robert,Lee Alan,Steinberg Michael L.,Valle Luca F.,Sachdeva Ankush,Romero Tahmineh,Calais Jeremie,Czernin Johannes,Nickols Nicholas G.,Kishan Amar U.^ORCID

Funder

Janssen Pharmaceuticals Inc

Publisher

Elsevier BV

Reference10 articles.

1. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials;Niraula;J Clin Oncol,2013

2. Review of prospective trials assessing the role of stereotactic body radiation therapy for metastasis-directed treatment in oligometastatic genitourinary cancers;Huynh;Eur Urol Oncol,2023

3. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial;Tang;JAMA Oncol,2023

4. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial;Phillips;JAMA Oncol,2020

5. Re: Apalutamide for metastatic, castration-sensitive prostate cancer;Taneja;J Urol,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radiotherapie bei viszeraler Metastasierung;Forum;2024-09-06

2. Prostate-Specific Membrane Antigen PET/CT–Guided, Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer;Journal of Nuclear Medicine;2024-08-01

3. Oligometastatic Recurrent Prostate Cancer: Whether To Intensify Treatment or Not;European Urology;2024-06